Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders

Key Findings:  The assigned medication was administered for 5 months. Significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and QOL was observed in the total study cohort, regardless of treatment assignment

Type of Study:  Human Trial

Study Sample Size:  25

Study Result:  Positive

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC)

Phytocannabinoid Source:  Unspecified

Chemotype:  Chemotype III

Form of Administration:  Not Applicable

Sub-Ratio: 1:20 and 1:6 (THC:CBD)

Dosage: Taken over 5 mo, two CBD enriched 5% oil formulations were compared: one with 0.25% THC( 20:1 group), the other with 0.83% THC (6:1 group)

Study Location(s):  Israel

Year of Pub:  2018

Link to study